These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 32291503)

  • 1. Role of Conversion Surgery for Unresectable Pancreatic Cancer After Long-Term Chemotherapy.
    Tsuchiya N; Matsuyama R; Murakami T; Yabushita Y; Sawada Y; Kumamoto T; Endo I
    World J Surg; 2020 Aug; 44(8):2752-2760. PubMed ID: 32291503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresectable pancreatic cancer after gemcitabine/nab-paclitaxel.
    Shibuki T; Otsuka T; Shimokawa M; Nakazawa J; Arima S; Fukahori M; Miwa K; Okabe Y; Koga F; Ueda Y; Kubotsu Y; Makiyama A; Shimokawa H; Takeshita S; Nishikawa K; Komori A; Otsu S; Hosokawa A; Sakai T; Oda H; Kawahira M; Arita S; Honda T; Taguchi H; Tsuneyoshi K; Kawaguchi Y; Fujita T; Sakae T; Nio K; Ide Y; Ureshino N; Shirakawa T; Mizuta T; Mitsugi K
    Sci Rep; 2024 Jul; 14(1):16906. PubMed ID: 39043707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing Indications for Conversion Surgery Based on Analysis of 454 Consecutive Japanese Cases with Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel: A Single-Center Retrospective Study.
    Ushida Y; Inoue Y; Oba A; Mie T; Ito H; Ono Y; Sato T; Ozaka M; Sasaki T; Saiura A; Sasahira N; Takahashi Y
    Ann Surg Oncol; 2022 Aug; 29(8):5038-5050. PubMed ID: 35294658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant-modified FOLFIRINOX vs nab-paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection.
    Wolfe AR; Prabhakar D; Yildiz VO; Cloyd JM; Dillhoff M; Abushahin L; Alexandra Diaz D; Miller ED; Chen W; Frankel WL; Noonan A; Williams TM
    Cancer Med; 2020 Jul; 9(13):4711-4723. PubMed ID: 32415696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
    Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
    Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Recent important insights into treatment of pancreatic cancer].
    Abe N; Sugiyama M; Atomi Y
    Gan To Kagaku Ryoho; 2005 May; 32(5):617-23. PubMed ID: 15918560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Multidisciplinary Therapy with Gemcitabine and Nab-Paclitaxel for Unresectable Pancreatic Cancer].
    Motoi F; Takadate T; Maeda S; Ariake K; Masuda K; Ishida M; Fukase K; Mizuma M; Ohtsuka H; Sakata N; Hayashi H; Nakagawa K; Morikawa T; Naitoh T; Unno M
    Gan To Kagaku Ryoho; 2017 Nov; 44(12):1241-1244. PubMed ID: 29394594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic factors and adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma.
    You DD; Lee HG; Heo JS; Choi SH; Choi DW
    J Gastrointest Surg; 2009 Sep; 13(9):1699-706. PubMed ID: 19582512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resection of Borderline Resectable and Locally Advanced Pancreatic Adenocarcinomas after Neoadjuvant Chemotherapy.
    Addeo P; Rosso E; Fuchshuber P; Oussoultzoglou E; De Blasi V; Simone G; Belletier C; Dufour P; Bachellier P
    Oncology; 2015; 89(1):37-46. PubMed ID: 25766660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of Recent Improvement of Survival Outcomes in Patients with Pancreatic Cancer Who Underwent Upfront Surgery.
    Jung JH; Won SH; Jung K; Lee JS; Lee JC; Kim JW; Yoon YS; Hwang JH; Han HS; Kim J
    Gut Liver; 2024 Jul; 18(4):737-746. PubMed ID: 38146258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcomes of neoadjuvant gemcitabine, nab-paclitaxel, and S1 (GAS) in borderline resectable pancreatic cancer with arterial contact: Results from a phase II trial.
    Uemura K; Kondo N; Sudo T; Sumiyoshi T; Shintakuya R; Okada K; Baba K; Harada T; Murakami Y; Takahashi S
    J Hepatobiliary Pancreat Sci; 2024 May; 31(5):351-362. PubMed ID: 38156372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival Outcomes Associated With Clinical and Pathological Response Following Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Chemotherapy in Resected Pancreatic Cancer.
    Macedo FI; Ryon E; Maithel SK; Lee RM; Kooby DA; Fields RC; Hawkins WG; Williams G; Maduekwe U; Kim HJ; Ahmad SA; Patel SH; Abbott DE; Schwartz P; Weber SM; Scoggins CR; Martin RCG; Dudeja V; Franceschi D; Livingstone AS; Merchant NB
    Ann Surg; 2019 Sep; 270(3):400-413. PubMed ID: 31283563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. R0 resection following chemo (radio)therapy improves survival of primary inoperable pancreatic cancer patients. Interim results of the German randomized CONKO-007± trial.
    Fietkau R; Grützmann R; Wittel UA; Croner RS; Jacobasch L; Neumann UP; Reinacher-Schick A; Imhoff D; Boeck S; Keilholz L; Oettle H; Hohenberger WM; Golcher H; Bechstein WO; Uhl W; Pirkl A; Adler W; Semrau S; Rutzner S; Ghadimi M; Lubgan D
    Strahlenther Onkol; 2021 Jan; 197(1):8-18. PubMed ID: 32914237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival benefit of conversion surgery for patients with initially unresectable pancreatic cancer who responded favorably to nonsurgical treatment.
    Asano T; Hirano S; Nakamura T; Okamura K; Tsuchikawa T; Noji T; Nakanishi Y; Tanaka K; Shichinohe T
    J Hepatobiliary Pancreat Sci; 2018 Jul; 25(7):342-350. PubMed ID: 29797499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pancreatectomy with major arterial resection after neoadjuvant chemoradiotherapy gemcitabine and S-1 and concurrent radiotherapy for locally advanced unresectable pancreatic cancer.
    Amano R; Kimura K; Nakata B; Yamazoe S; Motomura H; Yamamoto A; Tanaka S; Hirakawa K
    Surgery; 2015 Jul; 158(1):191-200. PubMed ID: 25900035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of gemcitabine/nab-paclitaxel/S-1 combination neoadjuvant chemotherapy for patients with borderline resectable pancreatic cancer with arterial contact.
    Kondo N; Uemura K; Sudo T; Hashimoto Y; Sumiyoshi T; Okada K; Seo S; Otsuka H; Murakami Y; Takahashi S
    Eur J Cancer; 2021 Dec; 159():215-223. PubMed ID: 34781169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term results of adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic carcinoma.
    Murakami Y; Uemura K; Sudo T; Hashimoto Y; Nakashima A; Kondo N; Nakagawa N; Sueda T
    J Surg Oncol; 2012 Aug; 106(2):174-80. PubMed ID: 22331838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma.
    Maggino L; Malleo G; Marchegiani G; Viviani E; Nessi C; Ciprani D; Esposito A; Landoni L; Casetti L; Tuveri M; Paiella S; Casciani F; Sereni E; Binco A; Bonamini D; Secchettin E; Auriemma A; Merz V; Simionato F; Zecchetto C; D'Onofrio M; Melisi D; Bassi C; Salvia R
    JAMA Surg; 2019 Oct; 154(10):932-942. PubMed ID: 31339530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparisons of different neoadjuvant chemotherapy regimens with or without stereotactic body radiation therapy for borderline resectable pancreatic cancer: study protocol of a prospective, randomized phase II trial (BRPCNCC-1).
    Gao S; Zhu X; Shi X; Cao K; Bian Y; Jiang H; Wang K; Guo S; Zhang H; Jin G
    Radiat Oncol; 2019 Mar; 14(1):52. PubMed ID: 30917842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Role of Conversion Surgery for Unresectable Gastric Cancer.
    Fukuchi M; Ishiguro T; Ogata K; Suzuki O; Kumagai Y; Ishibashi K; Ishida H; Kuwano H; Mochiki E
    Ann Surg Oncol; 2015 Oct; 22(11):3618-24. PubMed ID: 25663597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.